Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216521 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3HTR4CYP2D6 | |
| SCHEMBL23215572 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3HTR4CYP2D6 | |
| SCHEMBL23215612 | 0.85 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3HTR4 | |
| SCHEMBL23216570 | 0.85 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3HTR4 | |
| SCHEMBL23214860 | 0.85 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3HTR4 | |
| Trifluoroacetic Acid SCHEMBL23215574 | 0.81 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23215571 | 0.81 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23216520 | 0.81 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23216406 | 0.78 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL23230793 | 0.76 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SLC6A4 1866/4885SLC6A2 1553/4885SLC6A3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.